Lisata Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$1.09next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly16MTarget: Sufficient capital to fund operations through key clinical milestones
Annual Revenue Annually170KTarget: N/A (Clinical-stage pre-revenue biotech)
Annual Net Loss from Continuing Operations Annually-13.6MTarget: Prudent expense management to extend cash runway
Watch Items
- Kuva Labs Tender Offer Financing ExecutionTrigger: Failure of Kuva Labs to secure committed debt or equity financing to fund the $4.00 per share cash considerationAction: Re-evaluate standalone clinical development plan and alternative strategic transactions
- Phase IIa Glioblastoma Multiforme (GBM) Trial EnrollmentTrigger: Completion of enrollment, 90% enrollment, or sponsor-initiated termination of Protocol LSTA1-GBM-2AAction: Triggers the first CVR milestone payment of $1.25 per share to stockholders
- Certepetide New Drug Application (NDA) Filing or AcceptanceTrigger: Filing or regulatory acceptance of an NDA for certepetide by any global governmental authorityAction: Triggers the second CVR milestone payment of $1.75 per share to stockholders
Research as of 20 Jun 2026